

Prothrombin Time (INR) Home Monitoring Device

ACG: A-0650 (AC)
[Link to Codes](#)

- Clinical Indications
- Alternatives
- Evidence Summary
 - Background
 - Criteria
- References
- Codes

Clinical Indications

- Prothrombin time (INR) home monitoring device may be indicated when **ALL** of the following are present(1)(2)(3)(4)(5)(6):
 - Anticoagulation with oral vitamin K antagonist (eg, warfarin) has already been used for 3 months or longer.(17)(18) [\[A\]](#)
 - Anticoagulation with oral vitamin K antagonist (eg, warfarin) needed for 6 more months or longer(17)(30)
 - Appropriate and motivated patient or caregiver for INR home monitoring (including adequate visual acuity, manual dexterity, and mental ability)(9)
 - Home monitoring program is characterized by **1 or more** of the following(31)(32)(33):
 - Self-management, involving self-testing as well as dose adjustment based on algorithm provided by prescribing physician or specialty clinic(18)
 - Self-testing, involving home testing of INR but reporting values to centralized service that prescribes recommended dose adjustment, if any(14)(15)(17)
 - Required training of patient or caregiver has been scheduled, with assessment of competence in performing home monitoring.(17)(18)(34)(35)

Alternatives

- Alternatives include:
 - Anticoagulation with oral vitamin K antagonist (eg, warfarin) monitoring via physician office or specialty clinic(26)(31)(33)(36)
 - Newer anticoagulation agents for which intensive monitoring is not required, if appropriate for clinical condition(11)(37)(38)(39)(40)

Evidence Summary

Background

Oral anticoagulation therapy with vitamin K antagonists has been shown to reduce subsequent thromboembolic events in a variety of clinical settings.(7)(8) **(EG 1)** The narrow therapeutic range of vitamin K antagonists and the wide variation in individual dose-response require patients on extended therapy to undergo regular testing and possible dose readjustment to ensure that anticoagulation is sufficient to prevent thrombosis but not at such a high level as to cause bleeding.(7)(9)(10) **(EG 1)** The advent of portable devices to accurately measure anticoagulation from capillary whole blood via the INR has led to the ability of patients or their caregivers, if motivated and trained, to monitor anticoagulation at home (patient self-testing), and even to make necessary dose adjustments based on algorithms from the patient's provider (patient self-management).(11)(12)(13) **(EG 1)** Interactive patient support via the internet is also available.(14)(15) **(EG 2)** These devices usually store multiple measurements with a date and time stamp, and can also transmit such information electronically.(16) **(EG 2)**

Criteria

For anticoagulation with an oral vitamin K antagonist that has already been used for 3 months or longer, evidence demonstrates at least moderate certainty of at least moderate net benefit. **(RG A1)** Systematic reviews and meta-analyses have concluded that patient self-testing and self-management using approved INR home monitoring devices is at least equivalent to management by usual care. It is a safe option for suitable patients of all ages who have used oral vitamin K antagonists for at least 3 months and is associated with decreased mortality, decreased major complications, and increased amount of time spent by the patient in a therapeutic range of

anticoagulation without increased risk for a serious bleeding event.(8)(13)(19)(20)(21) **(EG 1)** Safety and effectiveness of home monitoring have been demonstrated in both children and elderly patients.(17)(18)(22)(23) **(EG 1)** However, studies do not address the question of whether home monitoring is safe during the high-risk initiation phase.(1)(9)(20) **(EG 1)** A prospective cohort study of 1140 adult patients who self-managed use of vitamin K antagonists concluded, after a network meta-analysis that included 6 major studies, that self-management was comparable to standard care and to new oral anticoagulants in terms of death, thromboembolic events, and major bleeding, demonstrating that self-management of properly trained patients (including those with atrial fibrillation, mechanical heart valves, venous thrombosis, and the elderly) can be effective and safe in a long-term real-life setting.(24) **(EG 1)** A prospective, randomized, controlled, open-label trial that included 114 patients found that a self-management program led by pharmacists, as compared with usual care at a specialty anticoagulation clinic, resulted in significant improvement in 4 of 5 quality-of-life measures, reduction in the time spent performing INR monitoring, and maintenance of a level of anticoagulation similar to that of the usual-care group.(25) **(EG 1)** A randomized controlled blinded study of 310 patients on long-term warfarin found that self-management via a validated home individualized algorithm performed at least as well as usual care in maintaining the INR within a target range; there were significantly fewer extreme readings and less INR variability in the self-management group.(26) **(EG 1)** Regarding patients with mechanical heart valves, a meta-analysis that included 5 randomized controlled trials and 2219 patients found that self-testing and self-management, as compared with conventional care, was associated with improvement in the quality of oral anticoagulant therapy by increasing time spent in the therapeutic range and decreasing rates of thromboembolic events and mortality, with no increase in hemorrhage.(27) **(EG 1)** A matched cohort study of 615 patients with mechanical heart valves found that, after 5 years of follow-up, patient self-management (which included INR self-testing) of oral anticoagulant therapy with vitamin K antagonists was associated with a lower risk of all-cause mortality compared with conventional management.(28) **(EG 2)** However, a randomized trial that included 2922 patients who were taking warfarin due to mechanical heart valves or atrial fibrillation compared weekly INR monitoring at home with monthly testing in a clinic and found no significant difference between the groups over a period of 2 to 4.75 years in time to a first major event (stroke, major bleeding episode, or death), which was the primary study outcome. The self-testing group demonstrated small but statistically significant improvements in percentage of time that INR was in target range, as well as in patient satisfaction with anticoagulation therapy.(29) **(EG 1)** A national guideline recommends that patients on long-term warfarin who are motivated and demonstrate competency in related procedures be considered for patient self-testing or patient self-management.(11) **(EG 2)** A specialty society guideline recommends patient INR self-management for patients treated with vitamin K antagonists who are motivated and can demonstrate competency in self-management strategies, including use of the self-testing equipment.(4) **(EG 2)**

References

- Jones S, Monagle P, Manias E, Bruce AA, Newall F. Quality of life assessment in children commencing home INR self-testing. *Thrombosis Research* 2013;132(1):37-43. DOI: 10.1016/j.thromres.2013.05.011. [Context Link 1, 2] View abstract...
- Atrial Fibrillation and Heart Valve Disease: Self-Monitoring Coagulation Status Using Point of Care Coagulometers (the CoaguChek XS System). NICE Diagnostic Guidance DG14 [Internet] National Institute for Health and Care Excellence. 2017 Dec Accessed at: <https://www.nice.org.uk/guidance>. [accessed 2022 Oct 21] [Context Link 1]
- Lip GYH, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. *Chest* 2018;154(5):1121-1201. DOI: 10.1016/j.chest.2018.07.040. (Reaffirmed 2022 Jul) [Context Link 1] View abstract...
- Witt DM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Advances* 2018;2(22):3257-3291. DOI: 10.1182/bloodadvances.2018024893. (Reaffirmed 2022 Jul) [Context Link 1, 2] View abstract...
- Corrochano M, et al. Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up. *BMC Cardiovascular Disorders* 2020;20(1):166. DOI: 10.1186/s12872-020-01448-7. [Context Link 1] View abstract...
- Kow CS, Sunter W, Bain A, Zaidi STR, Hasan SS. Management of outpatient warfarin therapy amid COVID-19 pandemic: a practical guide. *American Journal of Cardiovascular Drugs* 2020;20(4):301-309. DOI: 10.1007/s40256-020-00415-z. [Context Link 1] View abstract...
- Craig JA, Chaplin S, Jenks M. Warfarin monitoring economic evaluation of point of care self-monitoring compared to clinic settings. *Journal of Medical Economics* 2014;17(3):184-190. DOI: 10.3111/13696998.2013.877468. [Context Link 1, 2] View abstract...
- Sharma P, et al. Is self-monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation. *BMJ Open* 2015;5(6):e007758. DOI: 10.1136/bmjopen-2015-007758. [Context Link 1, 2] View abstract...
- Bloomfield HE, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. *Annals of Internal Medicine* 2011;154(7):472-482. DOI: 10.1059/0003-4819-154-7-201104050-00005. [Context Link 1, 2, 3] View abstract...
- Burgwinkle P, Pigott V, Liska G, Koshy T. Follow the protocol: teaching patients to self-test. *Nursing* 2014;44(3):20-22. DOI: 10.1097/01.NURSE.0000443325.96478.40. [Context Link 1] View abstract...
- Jennings I, Kitchen D, Keeling D, Fitzmaurice D, Heneghan C, BCSH Committee. Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology. *British Journal of Haematology* 2014;167(5):600-607. DOI: 10.1111/bjh.13070. [Context Link 1, 2, 3] View abstract...
- Barcellona D, Fenu L, Marongiu F. Point-of-care testing INR: an overview. *Clinical Chemistry and Laboratory Medicine* 2017;55(6):800-805. DOI: 10.1515/cclm-2016-0381. [Context Link 1] View abstract...
- Heneghan CJ, et al. Self-monitoring and self-management of oral anticoagulation. *Cochrane Database of Systematic Reviews* 2016, Issue 7. Art. No.: CD003839. DOI: 10.1002/14651858.CD003839.pub3. [Context Link 1, 2] View abstract...
- Recommendations for Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation. Optimal Use Report [Internet] Canadian Agency for Drugs and Technologies in Health. 2C; 2011 Nov Accessed at: <https://www.cadth.ca/>. [accessed 2022 Oct 13] [Context Link 1, 2]

15. Bereznicki LR, Jackson SL, Peterson GM. Supervised patient self-testing of warfarin therapy using an online system. *Journal of Medical Internet Research* 2013;15(7):e138. DOI: 10.2196/jmir.2255. [Context Link 1, 2] View abstract...
16. Braun S, Spannagl M, Voller H. Patient self-testing and self-management of oral anticoagulation. *Analytical and Bioanalytical Chemistry* 2009;393(5):1463-1471. DOI: 10.1007/s00216-008-2225-3. [Context Link 1] View abstract...
17. Jones S, McLoughlin S, Piovesan D, Savoia H, Monagle P, Newall F. Safety and efficacy outcomes of home and hospital warfarin management within a pediatric anticoagulation clinic. *Journal of Pediatric Hematology/Oncology* 2016;38(3):216-220. DOI: 10.1097/MPH.0000000000000502. [Context Link 1, 2, 3, 4, 5] View abstract...
18. Bauman ME, Massicotte MP, Kuhle S, Siddons S, Bruce AA. EMPoWArEd: Edmonton pediatric warfarin self-management study. *Thrombosis Research* 2015;136(5):887-893. DOI: 10.1016/j.thromres.2015.08.026. [Context Link 1, 2, 3, 4] View abstract...
19. Heneghan C, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. *Lancet* 2012;379(9813):322-334. DOI: 10.1016/S0140-6736(11)61294-4. [Context Link 1] View abstract...
20. Cumberworth A, Mabvuure NT, Hallam MJ, Hindocha S. Is home monitoring of international normalised ratio safer than clinic-based monitoring? *Interactive Cardiovascular and Thoracic Surgery* 2013;16(2):198-201. DOI: 10.1093/icvts/ivs454. [Context Link 1, 2] View abstract...
21. Kennedy M. Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy. *Evidence-Based Nursing* 2017;20(1):17. DOI: 10.1136/eb-2016-102510. [Context Link 1] View abstract...
22. Siebenhofer A, Hemkens LG, Rakovac I, Spat S, Didjurgeit U, SPOG 60+ Study Group. Self-management of oral anticoagulation in elderly patients - effects on treatment-related quality of life. *Thrombosis Research* 2012;130(3):e60-e66. DOI: 10.1016/j.thromres.2012.06.012. [Context Link 1] View abstract...
23. Abassi H, et al. Health-related quality of life correlates with time in therapeutic range in children on anticoagulants with International Normalised Ratio self-monitoring. *Archives of Cardiovascular Diseases* 2020;113(12):811-820. DOI: 10.1016/j.acvd.2020.05.022. [Context Link 1] View abstract...
24. Nagler M, Bachmann LM, Schmid P, Raddatz Muller P, Wuillemin WA. Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. *PLoS ONE* 2014;9(4):e95761. DOI: 10.1371/journal.pone.0095761. [Context Link 1] View abstract...
25. Verret L, et al. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial. *Pharmacotherapy* 2012;32(10):871-879. DOI: 10.1002/j.1875-9114.2012.01116. [Context Link 1] View abstract...
26. Dignan R, Keech AC, GebSKI VJ, Mann KP, Hughes CF, Warfarin SMART Investigators. Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. *International Journal of Cardiology* 2013;168(6):5378-5384. DOI: 10.1016/j.ijcard.2013.08.054. [Context Link 1, 2] View abstract...
27. Xu Z, Wang Z, Ou J, Xu Y, Yang S, Zhang X. Two monitoring methods of oral anticoagulant therapy in patients with mechanical heart valve prosthesis: a meta-analysis. *Journal of Thrombosis and Thrombolysis* 2012;33(1):38-47. DOI: 10.1007/s11239-011-0626-1. [Context Link 1] View abstract...
28. Christensen TD, Skjoth F, Nielsen PB, Maegaard M, Grove EL, Larsen TB. Self-management of anticoagulant therapy in mechanical heart valve patients: a matched cohort study. *Annals of Thoracic Surgery* 2016;101(4):1494-1499. DOI: 10.1016/j.athoracsur.2015.09.084. [Context Link 1] View abstract...
29. Matchar DB, et al. Effect of home testing of international normalized ratio on clinical events. *New England Journal of Medicine* 2010;363(17):1608-1620. [Context Link 1] View abstract...
30. Gallagher J, Mc Carthy S, Woods N, Ryan F, O' Shea S, Byrne S. Economic evaluation of a randomized controlled trial of pharmacist-supervised patient self-testing of warfarin therapy. *Journal of Clinical Pharmacy and Therapeutics* 2015;40(1):14-19. DOI: 10.1111/jcpt.12215. [Context Link 1] View abstract...
31. Ansell J. Point-of-care patient self-monitoring of oral vitamin K antagonist therapy. *Journal of Thrombosis and Thrombolysis* 2013;35(3):339-341. DOI: 10.1007/s11239-013-0878-z. [Context Link 1, 2] View abstract...
32. Gaw JR, Crowley S, Monagle P, Jones S, Newall F. The economic costs of routine INR monitoring in infants and children—examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring. *Thrombosis Research* 2013;132(1):26-31. DOI: 10.1016/j.thromres.2013.04.028. [Context Link 1] View abstract...
33. Thompson JL, et al. Anticoagulation early after mechanical valve replacement: improved management with patient self-testing. *Journal of Thoracic and Cardiovascular Surgery* 2013;146(3):599-604. DOI: 10.1016/j.jtcvs.2012.03.088. [Context Link 1, 2] View abstract...
34. Larsen T. Nurses' instruction of patients in the use of INR-monitors for self-management of cardio-vascular conditions: Missed instructional opportunities. *Patient Education and Counseling* 2017;100(4):673-681. DOI: 10.1016/j.pec.2016.10.001. [Context Link 1] View abstract...
35. Moloney E, Craig D, Holdsworth N, Smithson J. Optimising clinical effectiveness and quality along the atrial fibrillation anticoagulation pathway: an economic analysis. *BMC Health Services Research* 2019;19(1):1007. DOI: 10.1186/s12913-019-4841-3. [Context Link 1] View abstract...
36. Holbrook A, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2 Suppl):e152S-e184S. DOI: 10.1378/chest.11-2295. (Reaffirmed 2022 May) [Context Link 1] View abstract...
37. Andrade JG, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. *Canadian Journal of Cardiology* 2020;36(12):1847-1948. DOI: 10.1016/j.cjca.2020.09.001. (Reaffirmed 2022 Aug) [Context Link 1] View abstract...
38. Alonso-Coello P, Zhou Q, Guyatt G. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison. *Thrombosis and Haemostasis* 2012;108(4):647-653. DOI: 10.1160/TH12-01-0027. [Context Link 1] View abstract...

39. New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients With Atrial Fibrillation. CADTH Therapeutic Review Recommendations [Internet] Canadian Agency for Drugs and Technologies in Health. 2012 Jun Accessed at: <https://www.cadth.ca/>. [accessed 2022 Oct 13] [Context Link 1]
40. January CT, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. *Circulation* 2019;140(2):e125-e151. DOI: 10.1161/CIR.0000000000000665. (Reaffirmed 2022 Jul) [Context Link 1] View abstract...
-

Codes

CPT®: 85610, 93792, 93793

HCPCS: G0248, G0249, G0250

CPT copyright 2022 American Medical Association. All rights reserved.

MCG Health
Ambulatory Care 27th Edition
Copyright © 2023 MCG Health, LLC
All Rights Reserved

Last Update: 9/21/2023 5:33:56 AM
Build Number: 27.2.2023092114759.013030